Loading company…
SN BioScience develops SN-38, an anticancer drug built on double core-shell technology, from Seongnam, South Korea.
Founded in 2017 and based in Seongnam, South Korea, SN BioScience Inc. uses double core-shell technology to research and develop its anticancer drug known as 'SN-38'. The company is at the Series B stage.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in